Neoadjuvant/chemo nivolumab wins EU approval for resectable PD-L1+ NSCLC
The European Commission (EC) has approved nivolumab (Opdivo) in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence with PD-L1 expression in cells tumors of at least 1%.1 The regulatory decision was supported by data from the Phase 3 CheckMate 816 study … Read more